Consensus statement for cancer patients requiring intensive care support

M. G. Kiehl 1, G. Beutel 2, B. Böll 3, D. Buchheidt 4, R. Forkert 5, V. Fuhrmann 6, P. Knöbl 7, M. Kochanek 3, F. Kroschinsky 8, P. La Rosée 9, T. Liebregts 10, C. Lück 2, U. Olgemoeller 11, E. Schalk 12, A. Shimabukuro-Vornhagen 3, W. R. Sperr 7, T. Staudinger 7, M. von Bergwelt Baildon 3, P. Wohlfarth 7, V. Zeremski 12, P. Schellongowski 7, Consensus of the German Society of Hematology and Medical Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN)

Received: 4 October 2017 / Accepted: 19 March 2018 / Published online: 27 April 2018 © The Author(s) 2018

Abstract
This consensus statement is directed to intensivists, hematologists, and oncologists caring for critically ill cancer patients and focuses on the management of these patients.

Keywords Hematological malignancy · Oncological malignancy · Critical illness · Intensive care treatment · Mechanical ventilation · ICU · ICU admission

Introduction and background
Cancer is the second leading cause of death worldwide. According to recent publications, the incidence of neoplasms is expected to increase requiring more health care resources.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00277-018-3312-y) contains supplementary material, which is available to authorized users.

1 Department of Internal Medicine I, Clinic Frankfurt/Oder GmbH, Müllroser Chaussee 7, 15236 Frankfurt (Oder), Germany
2 Hannover Medical School (MHH) Clinic for Hematology, Coagulation, Oncology and Stem Cell Transplantation, Carl-Neuberg-Straße 1, 30625 Hannover, Germany
3 Department of Internal Medicine I, University Hospital, Kerpener Str. 62, 50937 Cologne, Germany
4 III. Medical Clinic, Medical Faculty Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
5 Johanniter-Hospital, Johanniterstr. 3-5, 53113 Bonn, Germany
6 Clinic for Intensive Care Medicine, University Hamburg, Martinistr. 52, 20246 Hamburg, Germany
7 Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
8 Department of Internal Medicine I, University Hospital, Fetschertstr. 74, 01307 Dresden, Germany
9 Department of Internal Medicine III, Schwarzwald-Baar-Klinikum, Klinikstr. 11, 78052 Villingen-Schwenningen, Germany
10 Clinic for Stem Cell Transplantation, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
11 Department of Cardiology and Pulmonary Medicine, University Hospital, Robert-Koch-Str. 40, 37075 Göttingen, Germany
12 Department of Hematology and Oncology, University Hospital, Leipziger Str. 44, 39120 Magdeburg, Germany
In patients with hematological or oncological malignancies, the disease itself or intensive therapy may result in critical illness in a substantial number of patients. In 1999, the American College of Critical Care Medicine stated that patients with hematological or metastasized oncological malignancies are poor candidates for ICU admission with a mortality rate of up to 90%. Thus, refusal of ICU admission of these patients was the common procedure (Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine, 1999 [2]). However, within the last 25 years, cancer and ICU treatment clearly improved. As shown in recent reports, hospital mortality decreased to less than 40% in these critically ill patients with hematologic malignancies [3]. Thus, criteria for ICU admission have to be adjusted. Aim of this consensus statement is to provide a review of the recent literature and the development of practical recommendations to hematologists, oncologists, and intensive care specialists. Due to a series of practice-changing investigations on proper ventilation techniques in cancer patients with acute respiratory failure, we put a special emphasis on discussing this topic.

Methods

The consensus group was selected to represent the expertise in the field of critical care in cancer patients in Germany and Austria. Experts were sent by the German Society of Hematology and Medical Oncology (DGHO), the Austrian Society of Hematology and Oncology (OeGHO), the German Society of Internal Intensive and Emergency Medicine (DGIIN), and the Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN). All authors are actively supporting the “Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP)” Initiative (info@ichop.eu).

Consensus statements are based on an in-depth PubMed literature retrieval of English as well as German language literature with last access February 01, 2017. For medical heading terms (MeSH) identifying potential relevant literature, please see Appendix. Seven working groups (a: ICU transfer criteria and goals of therapy, b: respiratory failure, c: end of life decisions, d: stem cell transplant patients, e: infections, f: coagulation, and g: miscellaneous) prepared the draft proposals in a first round of consensus development. Working groups decided on references with relevant impact on guideline development, and every group member had to approve the draft guideline subchapter. Finally, the consensus statements were approved by the assembly of the members on March 2nd and 3rd 2017 in Vienna, Austria, a meeting hosted and sponsored by the OeGHO. All statements and manuscript wording underwent voting of the consensus assembly.

This guideline follows the structure and definitions of the ESCMID Guideline on Candida diseases [4–6]. It is in accordance with the GRADE and AGREE [7, 8] (Table 1).

All recommendations are given in boldface type.

### Prognosis and ICU admission criteria

#### Whom to admit to the ICU/eligibility and goals of therapy

Full-code ICU management (without limitations of ICU resources) should be offered to all critically ill cancer patients if long-term survival may be compatible with the general prognosis of the underlying malignancy (A-IIu)

This statement, of course, presumes that the acute condition may be reversed by ICU measures, and that age and comorbidities of patients do not contradict such an approach. Typically, full-code management applies to patients with curative therapeutic options, those in remission of their malignancy, as well as to patients in whom cure is not likely but the expected life-span is substantial [3, 9]. It has been suggested in an earlier consensus that an assumed

| Table 1 | Strength of the recommendation and quality of evidence |
|---------|------------------------------------------------------|
| Strength | Recommendation                                      |
| A       | Strong recommendation for use                       |
| B       | Moderate recommendation for use                      |
| C       | Marginal recommendation for use                      |
| D       | Recommendation against use                          |
| Quality of evidence |                                         |
| I       | Evidence from at least 1 properly designed randomized, controlled trial |
| IIa     | Evidence from at least 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple time series; or from dramatic results of uncontrolled experiments |
| III     | Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies |

* Added index: †: meta-analysis (or systematic review of RCT); ‡: transferred evidence, i.e., results from different patients “cohorts” or similar immune status situation; §: comparator group: historical control; ¶: uncontrolled trials; ‡: published abstract (presented at an international symposium or meeting)
prognosis of 1 year may be used as cutoff for clinical decision making with regard to full-code status [10]. The authors of this manuscript believe this number is arbitrary and may be regarded as basis for individual considerations only.

**Patients with poor performance status not eligible for further anti-cancer therapy, dying patients, as well as those rejecting critical care treatment should not be admitted to the ICU in general (A-III)**

For patients not fulfilling the above-described criteria for full-code ICU management or ICU refusal, time-limited ICU trials or pre-defined do-not-escalate decisions (e.g., do-not-intubate or do-not-attempt-resuscitation) may be adequate options (B-IIu)

In a prospective trial on patients with intermediary prognosis (non-palliative, non-bedridden, non-full-code patients), those with worsening organ failure scores after days 5 of ICU therapy had a high risk of dying. The authors suggested to offer these patients a full-code ICU trial with re-evaluation of the goals of therapy after at least 6 days [9]. We would like to point out that almost all patients who died after day 5 had treatment-limitation decisions. Therefore, it remains unknown what their course would have been in case of further full-code management. Furthermore, data on cancer patients with poor prognosis suggest that the optimal duration of time-limited ICU trials seems to differ largely between patients with solid tumors and hematologic malignancies [11]. Thus, proposing a fixed interval from admission to re-evaluation of the goals of ICU therapy in patients undergoing time-limited ICU trials may not be generally appropriate.

**When to admit to the ICU, indications and screening for organ dysfunction**

Several observational investigations on cancer patients with septic complications and respiratory failure indicate that early ICU admissions and early interventions, respectively, are associated with improved survival [3, 12–16]. Thus, early identification of patients at risk for critical deterioration seems crucial. Severity of illness scores can only be used for describing groups of patients and should, therefore, not be used in individual clinical decision making with regard to ICU admissions or prognostication.

Cancer patients should be considered for ICU admission in case of manifest or incipient acute organ dysfunction(s) (A-Ilu)

Cancer ward patients at risk should be screened for the presence of sepsis daily (A-IIt)

Cancer ward patients at risk should be screened for the presence of acute organ dysfunction(s) daily (A-Ilu)

**Recommendations for local structures and educational matters**

Mortality of ICU cancer patients has markedly dropped over the last decades, presumably due to improved general ICU management, improved diagnostic and therapeutic strategies for several cancer-specific situations, as well as refined admission criteria [10, 17, 18]. Yet, prognostication of cancer patients and adequate patient selection remain far from perfect [19].

Centers should establish local admission criteria for critically ill cancer patients as well as standardized admission procedures, such as joint assessment by cancer specialists and intensivists, if available (A-III)

A recent Brazilian investigation showed an independent correlation between daily joint rounds of cancer specialists and intensivists as well as the number of protocols with lower mortality and more efficient resource use [20]. This is supported by Nassar and coworker stating that regular meetings may reduce possible conflicts between intensivists and oncologists [21].

Centers should establish daily joint rounds of cancer specialists and intensivists as well as standard-operating procedures for the management of frequent medical conditions of critically ill cancer patients (A-Ilu)

Although a recent study by Soares and colleagues failed to identify ICU volume as a prognostic marker for ICU survival [20], the majority of available studies demonstrate a significant association of case volume and ICU mortality in cancer patients with septic shock or acute respiratory failure [22–24]. This effect might be linked to expertise and specific processes of care. However, some of the available observational studies may not have accounted for potential confounders related to ICU organization, structure, and process of care. Ultimately recognizing and developing “critical care of cancer patients” as a medical subspecialty may optimally serve the needs of affected patients [25]. Nevertheless, due to the fast-growing demand for critical care for cancer patients, the major practical challenge is how to provide high-quality and affordable care.
for all patients. Treating all critically ill cancer patients regardless of the underlying condition in specialized centers may not be feasible after all. Therefore, managing some of the rather common cancer-specific ICU problems, such as neutropenic sepsis, should become part of routine expertise for all intensive care specialists. However, in more specific situations, such as chemotherapy administration in critically ill patients with aggressive hematologic malignancies or caring for ICU patients after allogeneic stem cell transplant, transfer to specialized centers should be discussed.

Centers should establish joint continuous medical education of cancer specialists and intensivists (A-III)

Basic concepts of the care of critically ill cancer patients should be included into the curricula of both cancer specialists and intensivists (A-III)

All previous statements are summarized in Table 2.

### Acute respiratory failure (ARF)

#### Diagnostic work-up

With respect to the critical prognosis of ARF in cancer patients, especially in patients with ARF of unknown origin [29, 30], diagnostic procedures are of major clinical importance. A systematic diagnostic work-up may lead to a (high-probability) diagnosis in approximately 70–80% of patients with ARF [31, 32]. However, diagnostic procedures should not cause a delay in the start of adequate ARF therapy including prompt antibiotic treatment (modification) in the case of a (suspected) infection (A-III).

The diagnostic strategy should encompass a comprehensive analysis of the clinical course of the underlying malignancy, including data on mechanisms of immunosuppression, antineoplastic and antimicrobial treatment, and prophylaxis [31, 33].

Independent of the clinical presentation, chest computed tomography is recommended (A-IIt)

Bronchoscopy and a BAL-based diagnostic work-up including a broad range of both culture- and non-culture-based diagnostic methods should be added to noninvasive tests depending on pretest probabilities of clinical etiologies (if clinically feasible early after ICU admission and without causing clinical worsening) (A-I)

Table 3 provides a summary of diagnostic procedures in cancer patients with ARF.

#### Ventilatory strategies

Noninvasive ventilation (NIV) remains the first-line standard of care in acute exacerbate chronic pulmonary

| Table 2 | Admission to ICU, eligibility, and aims of therapy |
|---------|--------------------------------------------------|
| Intention | Clinical situation/intervention | SoR/QoE | Reference |
| I. | Defining ICU eligibility criteria and goals of therapy | Full-code ICU management in all critically ill cancer patients with prospect of long-term survival | A-IIu | [3] |
| II. | Defining ICU eligibility criteria and goals of therapy | ICU refusal in patients with poor performance status not eligible for further anti-cancer therapy, dying patients, as well as those rejecting critical care | A-III | |
| III. | Defining ICU eligibility criteria and goals of therapy | Time-limited ICU trial and/or do-not-escalate decisions in patients neither fulfilling full code nor refusal criteria | B-IIu | [9, 11] |
| IV. | Reducing mortality; indications for ICU admission | Early admission of patients with manifest or incipient acute organ dysfunction(s) to the ICU | A-IIu | [3, 12–16] |
| V. | Reducing mortality; early identification of ICU candidates | Daily sepsis screening in cancer ward patients at risk | A-IIt | [26, 27, 28] |
| VI. | Reducing mortality; early identification of ICU candidates | Daily screening for acute organ dysfunctions in cancer ward patients at risk | A-IIu | |
| VII. | Facilitating ICU admission decisions | Local ICU admission criteria and joint assessment by cancer specialists and intensivists | A-III | |
| VIII. | Reducing mortality; local structures | Establish daily rounds of cancer specialists and intensivists | A-IIu | [20] |
| IX. | Reducing mortality; local structures | Establish standard-operating procedures for frequent medical conditions of critically ill ICU cancer patients | A-IIu | [20] |
| X. | Reducing mortality; local structures | Admit critically ill cancer patients to experienced ICUs | A-IIu | [19, 20] |
| XI. | Continuous medical education | Establish joint continuous medical education of cancer specialist and intensivists | A-III | |
| XII. | Basic medical education/training | Include basic concepts on critically ill cancer patients into cancer specialists’ and intensivists’ curricula | A-III | |
disease (AECOPD) or acute cardiogenic pulmonary edema [35]. However, the role of NIV in hypoxic ARF is far less well documented. While a historic single-center randomized controlled trial (RCT) suggested superiority of NIV over conventional oxygen therapy in immunocompromised (mainly hematologic) patients with regard to intubation and survival rates [36], successive (mainly observational) studies have led to conflicting results. The 2015 “Clinical Practice Guidelines on noninvasive mechanical ventilation in ARF” on behalf of the German Society of Pneumology and Ventilatory Medicine acknowledge that NIV can be attempted to avoid intubation in immunosuppressed (including hemato-oncologic) patients. In this regard, it is of particular importance to respect common contraindications and termination, i.e., intubation criteria [35]. However, the respective guideline could not account for several meanwhile published investigations: First, a meta-analysis on 2380 mainly hematologic patients revealed that NIV as initial ventilator strategy was associated with lower mortality, whereas

Table 3 Invasive and noninvasive diagnostic procedures in ARF

| Procedure                                                                 | Bacteria                                                                 | Fungi                                                                 | Mycobacteria                          | Pneumocystis jiroveci                  | RSV, influenza | Herpesvirida            | Cytomegalovirus      | Epstein-Barr virus |
|----------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------|-------------------------|---------------------|---------------------|
| Blood cultures                                                            |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Multislice or high-resolution computed tomography (CT) scan of the lungs  |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| (in most cases without contrast media), (MRI of the lungs, if a pulmonary CT scan is not feasible) |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Echocardiography (cardiac status)                                          |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Sputum examination for                                                     | Bacteria                                                                 |                                                                      |                                        |                                        |                |                         |                     |                     |
| Induced sputum                                                             |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Nasopharyngeal aspirates                                                   |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Polymerase chain reaction blood test for                                  |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Circulating Aspergillus galactomannan                                     |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Serologic tests for                                                        | Chlamydia pneumoniae                                                     |                                                                      |                                        |                                        |                |                         |                     |                     |
| Urine antigen for                                                          | Mycoplasma pneumoniae                                                    |                                                                      |                                        |                                        |                |                         |                     |                     |
| BAL (samples should include by default)                                   |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • Cytospin preparation including Giemsa stain for cytological diagnostics and Gram stain |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • Bacteriological cultures (quantitative or semi-quantitative) including culture media to detect Legionella spp., mycobacteria and fungi |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • Calcofluor white or equivalent stain (assessment of fungi)              |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • (quantitative, if possible) PCR for Pneumocystis jirovecii              |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • direct immunofluorescence test for Pneumocystis jirovecii               |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • Aspergillus antigen (Galactomannan ELISA)                               |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| BAL (optional)                                                            | Mycobacterium tuberculosis PCR, atypical mycobacteria                     |                                                                      |                                        |                                        |                |                         |                     |                     |
| • PCR for cytomegalovirus, respiratory syncytial virus, influenza A/B virus, parainfluenza virus, human metapneumovirus, adenovirus, varicella zoster virus, and Pneumocystis jirovecii (quantitative) [34] |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| • Aspergillus antigen (Galactomannan ELISA; ODI (optical density index): 1.0) Panfungal or Aspergillus/mucormycetes PCR |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |
| Transbronchial biopsies                                                   |                                                                          |                                                                      |                                        |                                        |                |                         |                     |                     |

Adapted and modified from Azoulay et al., Am J Respir Crit Care Med 2010 [31]
this finding is a mere association and cannot be interpreted as proof of principle. Importantly, 61% (range 40 to 78) of patients experienced NIV failure with secondary intubation, which itself was associated with increased mortality [37]. Second, in a large multicenter observational investigation in 1004 cancer patients with ARDS, NIV failure occurred in 71% of patients and was, again, independently associated with mortality, while mortality of ARDS patients undergoing IMV per se had decreased to 52% in recent years [38]. Finally, a recent large multicenter landmark RCT compared the use of NIV to conventional oxygen in immunocompromised (mainly hematologic) patients with hypoxic ARF (acute cardiogenic pulmonary edema or hypercapnia, i.e., PaCO₂ > 50 mmHg excluded, pre-specified intubation criteria [39]). The trial did not show any clinical benefits or increased harms associated with NIV. However, the lower than expected mortality rate in the oxygen only group limited the power to detect significant differences, and a higher proportion of patients in the NIV group received high flow nasal oxygen intermittently, which may have limited the demonstrable effects of NIV. Risk factors for NIV failure in cancer patients are depicted in Table 4.

High flow nasal oxygen (HFNO) has recently been shown to be associated with reduced intubation (PaO₂/FiO₂ < 200) and mortality (PaO₂/FiO₂ < 300) rates in elderly patients with pneumonia and hypoxic ARF when compared to conventional oxygen therapy or NIV [41]. This effect was also observed in the subset of immunocompromised patients [42]. However, given conflicting data, the applicability of these findings in cancer patients, and specifically in those presenting with other etiologies than pneumonia, remains to be demonstrated [43, 44].

In case a NIV or HFNO trial is initiated in cancer patients with hypoxic ARF, common contraindications and/or the occurrence of pre-specified intubation criteria should lead to intubation and invasive mechanical ventilation without delay (A-Ilu).

Given the considerable failure rates of NIV and HFNO in hypoxic ARF and the lack of sufficient data on the safety of such therapies in regular wards, NIV and HFNO should not be attempted in this indication on a regular ward (B-III).

**End-of-life, palliative care**

Principles in palliative care and end-of-life (EOL) management are not different in cancer patients compared to critically ill patients without a malignancy as underlying disease (A-III). However, (i) patient’s wish, (ii) progressive (multi-) organ failure despite full-code ICU management and no chance of reversibility, or (iii) rapid progress of cancer disease without further treatment options have to be kept in mind and could change the treatment decision or treatment goals [45]. These issues have to be discussed between oncologists and the intensive care team in an interdisciplinary manner. In cancer patients admitted to an ICU, current treatment state and estimated prognosis may be unknown to the ICU team. Therefore, consultation of an oncologist is highly recommended to provide valid prognostic information (A-III).

Intensive care admissions often represent an additional burden for patients and families in situations without option for cure. Good communication is essential to allow patients and families to meet their preferences regarding EOL. According to the literature, too many EOL decisions are made too late [46]. Early integration of an interdisciplinary palliative care team for hospitalized patients with life-limiting disease leads to fewer ICU admissions (A-I) [47]. Furthermore, integration of pro-active palliative care on ICUs, including palliative care rounds, leads to a shorter length of stay on ICU or in the hospital (A-IIt) [48, 49].

To improve quality of EOL care in critically ill patients regarding important clinical questions, i.e., preparing for withdrawal, assessment and drug management of distress, discontinuation of treatment and monitoring, or dignity conserving care [50], the authors refer to published consensus recommendations [51, 52].

### Table 4

**Risk factors for NIV failure in cancer patients with acute respiratory failure**

| Prior to NIV                                      | During NIV                                      |
|--------------------------------------------------|------------------------------------------------|
| Vasopressor need                                 | Patient not tolerating NIV                      |
| Multiple organ failure                           | No improvement of ABG within 6 h                |
| Airway involvement by malignancy                 | Respiratory rate > 30/min                       |
| Acute respiratory distress syndrome              | NIV dependency ≥ 3 days                         |
| Unknown etiology of ARF                          | Clinical or respiratory deterioration           |
| Delayed onset of ARF                             | Unknown etiology of ARF                        |

Adopted and modified from Soares et al., Critical Care Clinics 2010 [40]

NIV, noninvasive ventilation; ARF, acute respiratory failure; ABG, arterial blood gas.
Special situations

Anticancer therapy during ICU

In some cases, for example pulmonary involvement due to high grade non-Hodgkin lymphoma, hyperleukocytosis, etc., despite ICU treatment initiation or completion of anticancer chemotherapy, immunochemotherapy or radiotherapy is necessary to improve patient's clinical situation. Such some decision needs intensive discussions between the responsible hemato-oncologist and intensivist. Again, we recommend joint assessments by cancer specialists and intensivists and that basic concepts of the care of critically ill cancer patients should be included into the curricula of both cancer specialists and intensivists.

Prevention and treatment of infections in critically ill cancer patients

Published guidelines on prevention, diagnosis, and treatment of infections in cancer patients do not specifically address critically ill cancer patients. In addition, few studies and current guidelines on infections in critically ill patients specifically address the particular requirements in the treatment of cancer patients (Table 5).

Resources on prevention and treatment of infections in cancer patients, which might be largely applicable to critically ill cancer patients, are guidelines on:

- Management of neutropenic patients in the intensive care unit [69]
- Prophylaxis of viral [57], bacterial [55], and fungal [56] infections including *Pneumocystis jirovecii* pneumonia [55]
- Unexplained fever in neutropenic patients [60] (new version in progress)
- Diagnosis of invasive fungal infections [70] (new version in progress)
- Treatment of invasive fungal infections [61] and *Pneumocystis jirovecii* pneumonia [62]
- Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients [63]
- Prophylaxis and treatment of infections in recipients of autologous [71] (new version in progress) and allogeneic stem cell transplant [26]
- Community-acquired respiratory viral infections [72]
- Management of central venous catheter-related infections [73]
- Gastrointestinal complications including neutropenic enterocolitis [74] (new version in progress).
- Infections of the central nervous system in patients with hematological disorders [75]
- The Surviving Sepsis Campaign (SSC) Guidelines for Management of Sepsis and Septic Shock recently published [76]. The guidelines published in 2014 on sepsis in neutropenic patients might be less appropriate since they are based on the 2012-ssc-guidelines [59].
- IDSA guidelines on immunization in patients with cancer [58]; guidelines on immunization by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) are under progress.
- Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy [68].

| Table 5 | Recommendations on prevention, diagnosis, and treatment of infections in cancer patients |
|---------|-------------------------------------------------------------------------------------|
| Intention | Clinical situation/Intervention | SoR/QoE | Reference |
| I. Reducing mortality | Treatment in close collaboration of intensivist with cancer specialist and ID specialist | AIIt | [53, 54] |
| II. Prevention of infections | Continuation of prophylactic antiviral, antibacterial and antifungal treatment upon ICU-admission, unless switch to therapeutic treatment or excessive organ toxicity | AIIt | [55, 56, 57] |
| III. Prevention of infections | Immunization only according to specific guidelines for patients with cancer | BIII | [58] |
| IV. Treatment | Treatment of critically ill patients with infections including neutropenic sepsis according to current guidelines for the treatment of sepsis and septic shock | AIIt | [59] |
| V. Anti-infective treatment | Anti-infective treatment according to recommendations for treatment of bacterial, fungal and viral infections in cancer patients | AIIr | [60–64] |
| VI. Reducing mortality | Recommendation against routine use of GCSF in neutropenic patients with pulmonary infiltrates | AIIr | [65–67] |
| VII Reducing mortality | Use of GCSF only in selected cancer patients according to current recommendations. | AIIt | [68] |
**Allogeneic stem cell transplant setting**

**Criteria for ICU admission**

The prognosis of allogeneic hematopoietic stem cell transplant (HSCT) patients admitted to an ICU has been significantly improved in the last years [77]. It is important to note that physicians of the primary hospital have to contact the patient’s transplant center immediately in case of critical illness. Allogeneic HSCT patients with early ICU admission or single organ dysfunction benefit from intensive care. However, patients with uncontrolled or refractory graft-versus-host disease (GvHD) should not be intubated for acute respiratory failure (A-III) [10, 78]. Thus, it is important to contact immediately patient’s transplant center.

For further information regarding isolation procedures, specific monitoring, as well as typical complications, please see supplement.

**Coagulation**

Venous thromboembolism (VTE), including deep-vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in cancer patients. An increased tumor burden results in a higher risk for VTE with the highest risk in patients receiving systemic chemotherapy or being hospitalized on surgical and medical floors.

Although there are no validated data on the risk assessment in cancer patients on the ICU, according to the American Society of Clinical Oncology guidelines, risk scores (Khorana Score, revised Khorana score, Vienna score and Protecht score) are helpful tools to identify patients at highest risk for VTE [79–81]. For further information on thromboprophylaxis in hospitalized patients with cancer, thromboprophylaxis in surgical patients with cancer, and treatment of thrombosis, please see Supplement Table S3 and accompanying text.

**Complications after new cancer drugs or cellular immunotherapy**

Pharmacological and cellular treatment of cancer is changing dramatically not only with benefits for patient’s outcome and comfort, but also with new toxicity profiles. The vast majority of adverse events can be classified as mild or moderate but there are also some cases of severe and life-threatening complications requiring ICU admission. Diagnosis and management of severe side effects after (monoclonal or bispecific) antibody treatment, tyrosine kinase inhibitors, immune checkpoint inhibitors, and chimeric antigen receptor-modified (CAR-) T cells were summarized recently in a concise review by the iCHOP group [82].

**Transfusions**

In order to prevent the transfusion-associated graft versus host reaction (GvHR), all cellular blood products have to be irradiated with ≥30 Gy for patients with lymphatic diseases, autologous/allogeneic stem cell transplantation, and all patients treated with nucleoside analogues (fludarabine, cladribine) [83]. Generally, to prevent acute hemolysis, AB0-identic transfusions should be carried out. However, after allogeneic HSCT, in exceptional cases, it is possible to transfuse major or minor incompatible blood products according to the AB0 blood group of the patient and the donor as stated in Supplement Table S1 [84, 85]. Pooled platelet concentrates have a higher risk of immunization. Therefore, we recommend the transfusion of apheresis platelet concentrates [84].

**Cytokine storm disease/Sepsis-like syndromes**

Cancer patients are at risk to suffer from rare sepsis-like syndromes such as hemophagocytic lymphohistiocytosis (HLH), cytokine release syndrome (CRS), drug reaction with eosinophilia and systemic syndromes (DRESS), or capillary leak syndrome (CLS) [86–89]. Infections, malignancy itself, and drugs are major triggers for these sepsis-mimicking syndromes. Diagnostic vigilance for early recognition is essential to reduce mortality. To validate diagnosis, we recommend to include blood differential (cytopenia, eosinophilia), ferritin, soluble IL2R, fibrinogen, and triglycerides in addition to the routine ICU lab admission panel in cancer patients with sepsis or sepsis-like syndromes in whom there is no apparent focus of sepsis [90, 91] (see Table 6 for HLH diagnostic criteria). Withholding the assumed trigger drug and immediate search for an underlying malignancy or infection are pivotal. HLH patients require immediate immunosuppression with corticosteroids to prevent further progression of organ failure [92]. Early consultation with an HLH expert to stratify treatment according to the most likely trigger is recommended (www.hlh-registry.org).

**Summary**

During the last years, outcome of patients with malignant hematological or oncological diseases requiring intensive care treatment has clearly improved. From recently published data, we conclude that the severity of the acute illness is more important with regard to short-term survival than the underlying type and stage of malignancy. Patients receiving intensive treatment of their malignancy should be considered for ICU treatment as other severely ill patients without cancer. Centers
Table 6  HLH diagnostic criteria [91]

HLH-2004 diagnostic criteria: ≥ 5 must be fulfilled
- Fever (≥ 38.3 °C)
- Splenomegaly
- Cytopenias in ≥ 2 lines (hb < 9 g/dL, plt < 100 × 10^9/L, neutrophils < 1.0 × 10^9/L)
- Ferritin ≥ 500 μg/L
- Hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides ≥ 265 mg/dL, fibrinogen < 1.5 g/L)
- Hemophagocytosis in bone marrow or spleen or lymph nodes
- Low or absent NK activity
- Soluble CD25 (soluble IL-2 receptor) ≥ 2400 U/mL

should establish local admission criteria for critically ill cancer patients as well as standardized admission procedures, such as joint assessment by cancer specialists and intensivists, allowing identification of patients and standardized transfer to the ICU. In some patients, time-limited ICU trials with pre-defined do-not-escalate decisions (e.g., do-not-intubate or do-not-attempt-resuscitation) may be an adequate option until final decision. This implements that critically ill cancer patients should be referred to experienced intensive care units. We strongly recommend establishing a local structure with daily joint rounds of cancer specialists and intensivists as well as standard-operating procedures for the management of frequent medical conditions in critically ill cancer patients.

Furthermore, centers should organize continuous medical education of cancer specialists and intensivists. Finally, basic concepts of the care of critically ill cancer patients should be included into the curricula of both cancer specialists and intensivists.

In addition, the early integration of an interdisciplinary palliative care team is an urgently necessary measure.

In order to improve the management of critically ill cancer patients, knowledge of current practices in German-speaking countries is of utmost interest. To produce more robust data, participation of treating centers in central patient registries, e.g., the iCHOP registry (info@ichop.eu), is highly recommended.

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548
2. Medicine TFeAToCACA (1999) Guidelines for intensive care unit admission, discharge, and triage. Task force of the American College of Critical Care Medicine. Society of Critical Care Medicine. Crit Care Med 27(3):633–638
3. Azoulay E, Mokart D, Pene F, Lambert J, Kouratchet A, Mayaux J et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 31(22):2810–2818
4. Comely OA, Bassetti M, Calandra T, Garbinj J, Kullberg BJ, Lortholary O, Meersseman J, Alkandaqlagi S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group (2012) ESCMID® guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37
5. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, Jensen HE, Lass-Flörl C, Richardson MD, Akova M, Bassetti M, Calandra T, Castagnola E, Comely OA, Garbino J, Groll AH, Herbrecht R, Hope WW, Kullberg BJ, Lortholary O, Meersseman W, Petrikos G, Roilides E, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group (2012) ESCMID® guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18:9–18
6. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Comely OA, Donnelly J, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group (2012) ESCMID® guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18:53–67
7. Brouwers MC, Kho ME, Brown GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L, for the AGREE Next Steps Consortium (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182(18):E839–E842
8. Brozek J, Akl E, Compatelli E, Kreis J, Terracciano L, Fiozzi A et al (2011) Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 66:8
9. Lecuyer L, Chevret S, Thierry G, Darmon M, Schlemmer B, Azoulay E (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35(3):808–814
10. Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Alesa B (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1(1):5
11. Shrimi MG, Ferkit BS, Scott DJ, Lee J, Barragan-Bradford D, Pollard T, Arabi YM, Al-Dorzi HM, Baron RM, Hunink MGM, Celis LA, Lai PS (2016) Time-limited trials of intensive care for critically ill patients with cancer: how long is long enough? JAMA Oncol 2(1):76–83
12. Gruson D, Vargas F, Hilbert G, Bui N, Maillot T, Mayet T, Pillet O, Chene G, Gikpi-Benissan G (2004) Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia. Intensive Care Med 30(5):965–971
54. Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Rieg S, Kupper MF (2016) Infectious diseases consultations can make the difference: a brief review and a plea for more infectious oncology (DGHO), study group interventional therapy of unexplained fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82(Suppl 2):S105–S117
55. Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Krüger W, Link H, Neumann S, Ostermann AH, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Südhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, Böhme A (2014) Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHOM). Ann Hematol 93(1):13–32
56. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P, 6th European Conference on Infections in Leukemia (ECIL-6), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (IChS) and The European LeukemiaNet (ELN) (2016) ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 71(9):2405–2413
57. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C et al (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogenetic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHOM). Ann Oncol 26(1):1–33
58. Bertz H, Auner HW, Weissinger F, Salwender HJ, Einsele H, Egerer G et al (2003) Antimicrobial therapy of febrile complications after high-dose chemo-radiotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHOM). Ann Hematol 82(Suppl 2):S167–S174
59. Azoulay E, Attalah H, Harf A, Schlemmer B, Dellaux C (2001) Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 120(5):1695–1701
60. Verhoef G, Boogaerts M (1991) Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome. Ann J Hematol 36(4):285–287
61. Karlin L, Darmon M, Thiery G, Cirola M, de Miranda S, Lefebvre A et al (2005) Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant 36(3):245–250
62. Vehreschild JJ, Bohme A, Cornely OA, Kahl C, Karthaus M, Krenzer KA et al (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHOM). Ann Oncol 25(9):1709–1718
63. Schnell D, Azoulay E, Benoit D, Cluzeau B, Demaret P, Ducassou S, Frange P, Lafaurie M, Legrand M, Meert AP, Mokart D, Naudin J, Pene F, Rabat F, Rabloux E, Ribaud P, Richard JC, Vincent F, Zahar JR, Darmon M (2016) Management of neutropenic patients in the intensive care unit (NEWBORNs EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SFZH), and the French Infectious Diseases Society (SPILF). Ann Intensive Care 6(1):90
64. Ruhnke M, Bohme A, Buchheidt D, Cornely O, Donnhiusen K, Einsele H et al (2012) Diagnosis of invasive fungal infections in haematology and oncology—guidelines from the Infectious Diseases Working Party in haematology and oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 23(4):823–833
65. Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S,
Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91(8):1161–1174

72. von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehners N, Schalk E, Mayer K (2016) Community acquired respiratory virus infections in cancer patients—guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology. Eur J Cancer 67:200–212

73. Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, Maschmeyer G, Karthaus M, Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (2014) Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology And Medical Oncology. Ann Oncol 25(5):936–947

74. Vehreschild MJ, Vehreschild JH, Hubel K, Hentrich M, Schmidt-Hieber M, Christopeit M et al (2013) Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol 24(5):1189–1202

75. Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamadé U, Hänel S, Wolf HH, Ruhnke M, Schwartz S, Maschmeyer G (2016) CNS modified guidelines in patients with hematological disorders (including allogeneic stem-cell transplantation)-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 27(7):1207–1225

76. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerger B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, de Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koy H, Lisboa TC, Machado FR, Marin J, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalese P, Nishida O, Osdorn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Schekel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman J, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45(3):486–552

77. Lengline E, Chevret S, Moreau AS, Pene F, Blot F, Bourhis JH et al (2015) Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 50(6):840–845

78. Saillard C, Blaise D, Mokart D (2016) Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. Bone Marrow Transplant 51(8):1050–1061

79. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907

80. Khorana AA, McCrae KR (2014) Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 133(Suppl 2):S35–S38

81. Verso M, Agnelli G, Bami S, Gasparini G, La Bianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecct score. Intern Emerg Med 7(3):291–292

82. Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M et al (2017) New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 21(1):89

83. Moroff G, Luban NL (1997) The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 11(1):15–26

84. Bundesärztekammer WBd (2014) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten

85. Cassens U, Eichler H, Kläter H, Kroll H, Schlenke P, Wiesneth M (2004) Stellungnahme der Sektion “Transplantation und Zelltherapie” zur Transplantation hämatopoetischer Stammzellen mit Blutgruppendifferenz. Transfus Med Hemother 31:5

86. Lachmann G, La Rosee P, Schenk T, Brunkhorst FM, Spies C (2016) Hemophagocytic lymphohistiocytosis : a diagnostic challenge on the ICU. Anaesthetist 65(10):776–786

87. Schnetzke U, Bossert T, Scholl S, Freesmeyer M, Hochhaus A, La Rosee P (2011) Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment. Ann Hematol 90(11):1353–1355

88. Deeren DH, Zachee P, Malbrain ML (2005) Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol 84(2):89–94

89. Frey NV, Porter DL (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Edu Program 2016(1):567–572

90. Lehnerb K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, la Rosée P, Weitzman S, Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997–1004

91. La Rosée PS, Kunert C, Hochhaus A (2013) Die hämophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches ERscheinungsbild und Diagnostik. Laboratoriumsmedizin 37(5):217–225

92. La Rosee P (2015) Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Edu Program 2015(1):190–196